NASDAQ$BCPC

Balchem Corporation · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Balchem reported solid growth in sales and earnings, driven by growth across all segments and strategic acquisitions.

Balchem Corporation reported third quarter net sales of $244.3 million, a 23.4% increase compared to the prior year quarter. GAAP net earnings were $25.2 million, resulting in GAAP earnings per share of $0.78. Adjusted EPS was $1.00. The company's growth was supported by sales growth in all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, as well as strategic initiatives such as the acquisition of Bergstrom.

  • Net sales increased by 23.4% to $244.3 million, with growth in all three segments.
  • Adjusted EBITDA increased by 11.2% to $53.8 million.
  • GAAP net earnings increased by 0.9% to $25.2 million, with GAAP EPS of $0.78.
  • Adjusted net earnings increased by 8.0% to $32.4 million, with adjusted EPS of $1.00.

Headline financials

Total Revenue

$244M

Previous: $198M+23.4%
EPS (adj)

$0.79

Previous: $0.78+1.3%
Capital Expenditures

-$35M

Previous: -$21.6M-62.0%
Free Cash Flow

-$9.7M

Previous: $3.45M-381.6%
Net Income

$25.2M

Previous: $25M+0.9%
Operating Income

$33.6M

Previous: $32.5M+3.4%
Gross Profit

$68.4M

Previous: $60.9M+12.3%
Cash & Equivalents

$56.5M

Previous: $90M-37.2%
Total Assets

$1.63B

Previous: $1.18B+38.5%
Stock-Based Comp

$2.95M

Previous: $2.9M+1.9%

Revenue & EPS history

Balchem · Revenue · Quarterly

$244M

Q3 2022+23.4%vs Q3 2021
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Balchem · $238M total across 3 segments · Q3 2022

  • Human Nutrition & Health
    $143M+28.3%
  • Animal Nutrition & Health
    $65.6M+16.7%
  • Specialty Products
    $29.6M+7.3%

Forward guidance

I am very pleased with how the Balchem team continues to manage through the current market conditions, and how we have shown resilience and the ability to deliver strong results, even in challenging times. We remain excited about our future and our ability to provide solutions for the health and nutritional needs of the world while acting as strong stewards of all of our stakeholders.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.0%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.9%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+25.0%

Q1 2014

Best reaction

-16.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-6.8%-7.0%-9.7%
Q4 2025-2.3%+2.6%-7.4%
Q3 2025+4.1%+3.9%+1.3%
Q1 2025-2.6%-1.5%+4.8%
Q4 2024+1.5%+7.0%-0.1%
Q3 2024+2.8%+1.6%+9.8%
Q2 2024+3.9%+1.5%-1.2%
Q1 2024-1.8%-3.0%-8.8%
Q4 2023+7.4%+5.0%+6.8%
Q3 2023-5.0%-4.1%+1.1%
Q2 2023+4.8%+5.0%+7.1%
Q1 2023+1.7%+0.5%+5.2%
Q4 2022-2.0%-0.2%-7.7%
Q3 2022-0.6%-0.5%+5.4%
Q2 2022-5.2%-6.6%+2.3%
Q1 2022+1.6%-0.9%-10.5%
Q4 2021+1.0%-0.7%+1.2%
Q3 2021-0.8%+2.3%+7.9%
Q2 2021-0.8%-2.5%+2.7%
Q1 2021-0.2%-0.1%+0.5%
Q4 2020+5.4%+6.4%+10.7%
Q3 2020-1.7%-0.5%+3.3%
Q2 2020+4.6%+4.7%+0.3%
Q1 2020-5.4%-3.9%-9.3%
Q4 2019-10.7%-13.3%-15.9%
Q3 2019+2.9%+1.2%-0.8%
Q2 2019-16.3%-15.9%-13.5%
Q1 2019+1.1%+4.0%+9.4%
Q4 2018+8.0%+12.4%+10.7%
Q3 2018-4.9%-4.9%-13.7%
Q2 2018+1.1%+1.3%+10.1%
Q1 2018-1.3%+2.2%+7.9%
Q4 2017+2.3%+5.9%+8.6%
Q3 2017+1.0%-0.7%+1.3%
Q2 2017-2.6%-3.9%-1.8%
Q1 2017-3.3%-5.3%-1.8%
Q4 2016+5.2%+2.2%-2.5%
Q3 2016-4.5%+0.8%+12.3%
Q2 2016+1.3%+2.0%+8.7%
Q1 2016+0.3%
Q4 2015-0.4%
Q3 2015-2.0%
Q2 2015+5.2%
Q1 2015-0.5%
Q4 2014-3.4%
Q3 2014+6.7%
Q2 2014+2.5%
Q1 2014+25.0%
Q4 2013+0.4%
Q3 2013-4.9%
Q2 2013+1.3%
Q1 2013-2.3%
Q4 2012+0.8%
Q3 2012-10.5%
Q2 2012+5.9%
Q1 2011+2.1%
Q4 2011+2.1%
Q1 2012+2.4%
Q1 2010-4.1%
Q4 2009-4.1%
Q3 2010-3.2%
Q3 2011-3.2%
Q2 2011+1.0%
Q4 2010+1.0%
Q2 2010+1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro